INS and type 2 diabetes mellitus: While we believe our study is the first to report the impact of using isCGM or other CGM technologies on alleviating the risks for hospitalisation for these macrovascular complications of type 2 diabetes, the underlying reasons for this favourable finding, and for the different outcomes in the intensive and non-intensive insulin treatment groups, remain to be elucidated.